Business Description
Verici Dx PLC
ISIN : GB00BM8HZD43
Share Class Description:
LSE:VRCI: Ordinary SharesTotal Employee Number:
15Description
Verici Dx PLC is the development of prognostic and diagnostic tests for kidney transplant patients. It is a commercial stage diagnostics company, transforming the outcomes of kidney transplants through a complementary suite of proprietary, edge tests. These form a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. It has developed a suite of blood-based tests for kidney transplant patients. The Group has one division being the development of prognostic and diagnostic tests for kidney transplant patients. The company's products are Tutivia, Clarava, Protega. The company's services are Next Generation Sequencing Services, Bioinformatics &Data Science Services.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.99 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -5.44 | |||||
Beneish M-Score | 22.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 51.9 | |||||
3-Year EPS without NRI Growth Rate | 50.3 | |||||
3-Year FCF Growth Rate | 48 | |||||
3-Year Book Growth Rate | -62.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.72 | |||||
9-Day RSI | 5.86 | |||||
14-Day RSI | 11.38 | |||||
3-1 Month Momentum % | -28.57 | |||||
6-1 Month Momentum % | -48.28 | |||||
12-1 Month Momentum % | -37.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.94 | |||||
Quick Ratio | 3.94 | |||||
Cash Ratio | 2.48 | |||||
Days Sales Outstanding | 112.06 | |||||
Days Payable | 341.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -107.1 | |||||
Shareholder Yield % | -78.34 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.41 | |||||
Operating Margin % | -190.47 | |||||
Net Margin % | -189.4 | |||||
EBITDA Margin % | -173.14 | |||||
FCF Margin % | -231.05 | |||||
OCF Margin % | -225.86 | |||||
ROE % | -142.3 | |||||
ROA % | -101.56 | |||||
ROIC % | -171.69 | |||||
3-Year ROIIC % | -297.24 | |||||
ROC (Joel Greenblatt) % | -764.23 | |||||
ROCE % | -137.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 65 | |||||
PS Ratio | 0.5 | |||||
PB Ratio | 1.17 | |||||
EV-to-EBIT | -1.11 | |||||
EV-to-EBITDA | -1.2 | |||||
EV-to-Revenue | 2.09 | |||||
EV-to-FCF | -0.9 | |||||
Earnings Yield (Greenblatt) % | -90.25 | |||||
FCF Yield % | -78.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verici Dx PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 2.718 | ||
| EPS (TTM) (£) | -0.009 | ||
| Beta | 0.319 | ||
| 3-Year Sharpe Ratio | -1.39 | ||
| 3-Year Sortino Ratio | -1.51 | ||
| Volatility % | 63.82 | ||
| 14-Day RSI | 11.38 | ||
| 14-Day ATR (£) | 0.000554 | ||
| 20-Day SMA (£) | 0.003613 | ||
| 12-1 Month Momentum % | -37.5 | ||
| 52-Week Range (£) | 0.003 - 0.00994 | ||
| Shares Outstanding (Mil) | 2,287.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verici Dx PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verici Dx PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-10-07 09:00 | In 77 days | ||
| Second quarter earnings results for 2026 | 2026-09-30 | In 69 days | ||
| General meeting for 2026 | 2026-07-28 10:30 | In 6 days | ||
| Fourth quarter earnings conference call for 2025 | 2026-07-08 15:30 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-06-29 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-29 | 0.00 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-10-07 09:00 | 0.01 (+3.57%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 0.01 (+0.00%) | ||
| General meeting for 2025 | 2025-07-29 10:30 | 0.01 (+0.00%) | ||
| Annual report for 2024 | 2025-06-30 | 0.01 (+0.00%) |
Show
Entries
Verici Dx PLC Frequently Asked Questions
What is Verici Dx PLC(LSE:VRCI)'s stock price today?
The current price of LSE:VRCI is £0.00. The 52 week high of LSE:VRCI is £0.01 and 52 week low is £0.00.
When is next earnings date of Verici Dx PLC(LSE:VRCI)?
The next earnings date of Verici Dx PLC(LSE:VRCI) is 2026-09-30 Est..
Does Verici Dx PLC(LSE:VRCI) pay dividends? If so, how much?
Verici Dx PLC(LSE:VRCI) does not pay dividend.
Press Release
Articles on Verici Dx PLC
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers